| |
Atrial |
No atrial |
p value |
| dilatation |
dilatation |
| Patients, N |
2,268 |
5,409 |
|
| Initial treatment |
| Thrombolytics |
76 (3.4%) |
53 (1.0%) |
<0.001 |
| LMWH |
1,630 (72%) |
4,606 (85%) |
<0.001 |
| Mean LMWH doses (IU/kg/day) |
183±41 |
183±37 |
0.93 |
| Initial therapy, UFH |
510 (23%) |
586 (11%) |
<0.001 |
| Inferior vena cava filter |
83 (3.7%) |
164 (3.0%) |
0.155 |
| Long-termtreatment |
| Vitamin K antagonists |
1,402 (62%) |
3,285 (61%) |
0.374 |
| LMWH |
721 (32%) |
1,907 (35%) |
0.004 |
| Mean LMWH doses (IU/kg/day) |
173±49 |
169±44 |
0.048 |
| 30-day outcome |
| Overalldeath |
98 (4.32%) |
114 (2.11%) |
<0.001 |
| Causes of death
|
| Pulmonary embolism |
42 (1.85%) |
17 (0.31%) |
<0.001 |
| Respiratory insufficiency |
9 (0.40%) |
12 (0.22%) |
0.181 |
| Sudden, unexpected |
4 (0.18%) |
5 (0.09%) |
0.327 |
| Bleeding |
5 (0.22%) |
10 (0.18%) |
0.747 |
| Other |
30 (1.32%) |
66 (1.22%) |
0.712 |
| Unknown |
8 (0.35%) |
4 (0.07%) |
0.005 |
|
